The stock of Curis, Inc. (NASDAQ:CRIS) is a huge mover today! The stock increased 5.67% or $0.14 during the last trading session, hitting $2.61. About 1.29M shares traded hands or 109.92% up from the average. Curis, Inc. (NASDAQ:CRIS) has risen 65.77% since February 26, 2016 and is uptrending. It has outperformed by 55.35% the S&P500.
The move comes after 7 months positive chart setup for the $333.87M company. It was reported on Oct, 1 by Barchart.com. We have $4.72 PT which if reached, will make NASDAQ:CRIS worth $270.43 million more.
Analysts await Curis, Inc. (NASDAQ:CRIS) to report earnings on November, 14. They expect $-0.11 earnings per share, down 175.00% or $0.07 from last year’s $-0.04 per share. After $-0.09 actual earnings per share reported by Curis, Inc. for the previous quarter, Wall Street now forecasts 22.22% negative EPS growth.
Curis, Inc. (NASDAQ:CRIS) Ratings Coverage
Out of 4 analysts covering Curis (NASDAQ:CRIS), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Curis has been the topic of 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. TH Capital maintained Curis, Inc. (NASDAQ:CRIS) on Monday, November 9 with “Buy” rating. Zacks downgraded the shares of CRIS in a report on Tuesday, September 1 to “Hold” rating. The rating was initiated by FBR Capital with “Outperform” on Tuesday, August 11. Zacks downgraded the shares of CRIS in a report on Monday, September 21 to “Sell” rating. Roth Capital maintained it with “Buy” rating and $5 target price in Monday, November 9 report.
According to Zacks Investment Research, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.”
Insitutional Activity: The institutional sentiment increased to 1.78 in Q2 2016. Its up 0.88, from 0.9 in 2016Q1. The ratio increased, as 8 funds sold all Curis, Inc. shares owned while 15 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 67.45 million shares or 4.41% less from 70.56 million shares in 2016Q1.
Salem Counselors, a North Carolina-based fund reported 10,000 shares. Springbok Capital Ltd Liability Co holds 1,100 shares or 0% of its portfolio. Citigroup holds 0% or 26,659 shares in its portfolio. Morgan Stanley accumulated 0% or 127,255 shares. Int Group Inc, a New York-based fund reported 64,240 shares. Victory Capital Inc accumulated 6,939 shares or 0% of the stock. First Eagle Invest Management Ltd Company accumulated 24.01 million shares or 0.1% of the stock. Tower Rech Cap Ltd Liability (Trc) has 0% invested in the company for 7,157 shares. Fmr Ltd Liability Co accumulated 0% or 15.92 million shares. Ladenburg Thalmann Fincl Svcs Inc holds 0% or 4,390 shares in its portfolio. Creative Planning has 30,000 shares for 0% of their US portfolio. Cormorant Asset Mgmt Lc holds 0.26% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 1.18 million shares. Moreover, Susquehanna Group Incorporated Limited Liability Partnership has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 25,154 shares. Moreover, Janney Montgomery Scott Ltd Limited Liability Company has 0.01% invested in Curis, Inc. (NASDAQ:CRIS) for 169,400 shares. Point72 Asset Limited Partnership last reported 1.10 million shares in the company.
Insider Transactions: Since May 26, 2016, the stock had 0 insider buys, and 2 selling transactions for $51,750 net activity. $26,400 worth of shares were sold by KAITIN KENNETH I on Thursday, May 26. GREENACRE MARTYN D had sold 15,000 shares worth $25,350.
CRIS Company Profile
Curis, Inc., incorporated on February 14, 2000, is a biotechnology company. The Firm is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.